Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00246415 · ClinicalTrials.gov registry record · Phase 2
A Placebo-Controlled Trial of Memantine for Alcohol Dependence
A Phase 2 study of Alcohol Abuse and Alcohol Dependence (Primary Condition), sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT00246415: Completed Phase 2 study of Alcohol Abuse and Alcohol Dependence (Primary Condition), sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
NCT00246415 is a Phase 2 study of Alcohol Abuse and Alcohol Dependence (Primary Condition) that has completed, run by National Institute on Alcohol Abuse and Alcoholism (NIAAA). The registered enrollment target is 90 participants, below the 711-participant average among 46 other Alcohol Abuse trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00246415, a Phase 2 study of Alcohol Abuse and Alcohol Dependence (Primary Condition), has completed, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to obtain a preliminary indication of the safety and effectiveness of oral memantine (40 mg/day) in alcohol dependent patients. This study is a 16-week study comparison of memantine and placebo in patients with alcohol dependence.
Conditions Studied
Interventions
- DRUG Memantine
Study Locations (1)
New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2002-11 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
What the finished NCT00246415 record still lists
NCT00246415 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 711-participant average among 46 other Alcohol Abuse trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Alcohol Abuse appearing as the primary indexed condition, and to 1 intervention - of which Memantine is the first listed.
NCT00246415 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00246415 about?
NCT00246415 is a clinical study titled "A Placebo-Controlled Trial of Memantine for Alcohol Dependence". The purpose of this study is to obtain a preliminary indication of the safety and effectiveness of oral memantine (40 mg/day) in alcohol dependent patients. This study is a 16-week study comparison of memantine and placebo in patients with alcohol dependence.
What is the current status of trial NCT00246415?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2002-11. Estimated completion is 2005-12.
What conditions does trial NCT00246415 study?
This clinical trial studies the following conditions: Alcohol Abuse, Alcohol Dependence (Primary Condition).
What interventions are being tested in trial NCT00246415?
The interventions under investigation include: Memantine (DRUG).
Who is sponsoring clinical trial NCT00246415?
This trial is sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA), which has 93 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00246415 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Abuse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00246415's enrollment target sits among peer trials
90 31st of 46 higher than 15 of 46 other Alcohol Abuse trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Abuse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial
RECRUITING · Phase 2
-
Antioxidant Replacement Therapy in Patients With Alcohol Abuse
COMPLETED · Phase 2
-
Mifepristone Treatment of Alcohol Use Disorder
COMPLETED · Phase 2
-
Therapeutic Substance Abuse Treatment in Pregnancy - 1
COMPLETED · Phase 2
-
Personalized Feedback Intervention for Latinx Drinkers With Anxiety
RECRUITING · NA
-
Adaptation and Evaluation of Bright Horizons
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia